Executive Summary

Azoth Analytics has released a research report titled "Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market (2024 Edition)" which provides a complete analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist industry in terms of market segmentation By Type (Tirzepatide, Semaglutide, Dulaglutide, and Other Types), By Distribution Channel (Clinics, Ambulatory Surgical Centers, and Hospitals), By Route of Administration (Oral, and Parenteral) By End-Use (Type 2 Diabetes, NASH, and Obesity), for the historical period of 2020-2023, the estimates of 2023 and the forecast period of 2024-2030.

The research report covers a detailed analysis of the Region (Americas, Europe, Asia Pacific, and Middle East and Africa) and Countries (United States, Canada, UK, Germany, France, Italy, India, China, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, and demand forecast. The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market showcased growth at a CAGR of 20.6% during 2020-2023. The market was valued at USD 18.75 Billion in 2022 which is expected to reach USD 133.5 Billion in 2030. The demand for GLP-1 agonists extends globally, with both developed and developing regions contributing to market growth. Emerging economies are witnessing a rising prevalence of T2DM, driving the need for effective diabetes management strategies, including GLP-1 agonist therapies. The market includes a variety of GLP-1 agonist drugs, both short-acting and long-acting formulations, offering different options for healthcare providers and patients. These drugs are administered via subcutaneous injection or, in some cases, orally.

GLP-1 agonists are known for their efficacy in improving glycemic control in patients with T2DM, often leading to reductions in HbA1c levels and fasting plasma glucose levels. Additionally, these drugs are associated with weight loss, making them particularly beneficial for obese individuals with diabetes.

Several GLP-1 agonists have demonstrated cardiovascular benefits in clinical trials, including reductions in major adverse cardiovascular events (MACE) such as heart attack, stroke, and cardiovascular death. These findings have contributed to the growing adoption of GLP-1 agonists in patients with T2DM and established cardiovascular disease (CVD) or high cardiovascular risk.

While GLP-1 agonists are primarily administered via subcutaneous injections, efforts are underway to develop alternative delivery methods, such as oral formulations and once-weekly injections, to improve patient adherence and convenience. These innovations aim to address potential barriers to treatment adherence and enhance patient satisfaction.



Scope of the Report

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market by Value (USD Million).

• The report presents the analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market for the historical period of 2020-2023, the estimated year 2023, and the forecast period of 2024-2030.

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Type (Tirzepatide, Semaglutide, Dulaglutide, and Other Types).

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Distribution Channel (Clinics, Ambulatory Surgical Centers, and Hospitals).

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Route of Administration (Oral, and Parenteral).

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by End-Use (Type 2 Diabetes, NASH, and Obesity).

• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Type, By Distribution Channel, By Route of Administration & By End-Use.

• Also, the major opportunities, trends, drivers, and challenges of the industry have been analyzed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report include Eli Lilly and Company, Pfizer, Sanofi, AstraZeneca PLC, Boehringer Ingelheim, and Novo Nordisk.

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology



2. Strategic Recommendations



3. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

3.1 Impact Analysis of Macro Economic Factors on Glucagon-Like Peptide 1 (GLP-1) Agonist Market

3.2 Pipeline Analysis of GLP-1 Agonist Market

3.3 Global Obesity Statistics 2022, in Millions

3.4 Diabetes Statistics

3.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Dashboard

3.6 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million)

3.7 Impact of COVID-19 on Glucagon-Like Peptide 1 (GLP-1) Agonist Market

3.8 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Type

3.8.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type Overview

3.8.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Tirzepatide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Semaglutide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Dulaglutide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Other Types, By Value, 2020H-2030F (USD Million & CAGR)

3.9 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

3.9.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

3.9.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

3.9.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

3.9.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

3.10 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

3.10.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

3.10.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

3.10.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

3.11 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

3.11.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

3.11.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

3.11.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

3.11.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)



4. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Regional Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot



5. Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

5.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

5.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

5.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

5.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

5.5 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

5.6 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

5.6.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

5.6.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

5.6.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

5.6.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

5.7 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

5.7.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

5.7.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

5.7.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

5.8 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

5.8.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

5.8.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

5.8.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

5.8.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

5.9 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

5.9.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

5.9.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.2.1 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

5.9.2.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.2.3 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.3.1 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.3.2 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.3.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

5.9.4 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.4.1 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.4.2 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.4.3 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel



6. Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

6.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

6.6 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

6.6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

6.6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

6.6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

6.6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

6.7 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

6.7.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

6.7.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

6.7.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

6.8 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

6.8.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

6.8.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

6.8.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

6.8.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

6.9 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

6.9.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

6.9.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.2.1 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.2.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.2.3 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.3.1 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.3.2 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.3.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.4 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.4.1 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.4.2 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.4.3 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.5 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.5.1 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.5.2 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.5.3 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.6 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.6.1 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.6.2 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.6.3 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use



7. Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

7.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

7.5 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

7.6 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

7.6.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

7.6.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

7.6.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

7.6.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

7.7 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

7.7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

7.7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

7.7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

7.8 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

7.8.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

7.8.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

7.8.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

7.8.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

7.9 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

7.9.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

7.9.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.2.1 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.2.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.2.3 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.3.1 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.3.2 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.3.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.4 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.4.1 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.4.2 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.4.3 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.5 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.5.1 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.5.2 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.5.3 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.6 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.6.1 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.6.2 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.6.3 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use



8. Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

8.5 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

8.6 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

8.6.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

8.6.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

8.6.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

8.6.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

8.7 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

8.7.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

8.7.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

8.7.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

8.8 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

8.8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

8.8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

8.8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

8.8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)



9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market

9.2 Drivers

9.3 Restraints

9.4 Trends



10. Industry Ecosystem Analysis

10.1 Porter's Five Forces Model



11. Competitive Positioning

11.1 Companies' Product Positioning

11.2 Market Share Analysis of Glucagon-Like Peptide 1 (GLP-1) Agonist Market

11.3 Company Profiles

11.3.1 Eli Lilly and Company

11.3.2 Pfizer

11.3.3 Sanofi

11.3.4 AstraZeneca PLC

11.3.5 Boehringer Ingelheim

11.3.6 Novo Nordisk

Custom Peptide Pool Service Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)...

The Custom Peptide Pool Service Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufac...

Cyclic Peptide Service Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)...

The Cyclic Peptide Service Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturer...

Global Glucagon-Like Peptide 1 (GLP-1) Agonist market (2024 Edition): Analysis by Type (Tirzepatide, Semaglutide, Dulaglutide, Others), End-Use (Type 2 Diabetes, NASH, Obesity), By Distribution Channel, By Route of Administration, By Region, By Country: Market Insights and Forecast (2020-2030)...

Executive Summary Azoth Analytics has released a research report titled "Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market (2024 Edition)" which provides a complete analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist industry in terms of market segmentation By Type (Tirze...

Standard Peptide Custom Synthesis Service Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)...

The Standard Peptide Custom Synthesis Service Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive land...

Global Incretin Based Drugs Market (2023 Edition): Analysis By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029) ...

Executive Summary Azoth Analytics has released a research report titled "Incretin Based Drugs Market (2023 Edition)" which provides a complete analysis of the global Incretin Based Drugs industry in terms of market segmentation By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Di...

Global Peptide Manufacturing and Development Services Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Peptide Manufacturing and Development Services Market: The report discusses everything a marketer requires before investing in the global Peptide Manufacturing and Development Services Market ...

Global Biosynthesis Peptide Drugs Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Biosynthesis Peptide Drugs Market: The report discusses everything a marketer requires before investing in the global Biosynthesis Peptide Drugs Market during the forecast period 2023-2030. It...

Global Chemical Synthesis Peptide Drugs Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Chemical Synthesis Peptide Drugs Market: The report discusses everything a marketer requires before investing in the global Chemical Synthesis Peptide Drugs Market during the forecast period 2...

Global Custom Peptide Library Synthesis Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Custom Peptide Library Synthesis Market: The report discusses everything a marketer requires before investing in the global Custom Peptide Library Synthesis Market during the forecast period 2...

2023-2028 Global and Regional Peptide Therapeutics Industry Status and Prospects Professional Market Research Report Standard Version...

The global Peptide Therapeutics market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this...